login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
TSCAN THERAPEUTICS INC (TCRX) Stock News
USA
- NASDAQ:TCRX -
US89854M1018
-
Common Stock
1.78
USD
-0.06 (-3.26%)
Last: 9/25/2025, 8:02:36 PM
1.81
USD
+0.03 (+1.69%)
After Hours:
9/25/2025, 8:02:36 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TCRX Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
9 days ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
23 days ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Participate in Upcoming Investor Conferences
23 days ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Participate in Upcoming Investor Conferences
5 months ago - By: Benzinga
What Analysts Are Saying About TScan Therapeutics Stock
6 months ago - By: Benzinga
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
a month ago - By: Zacks Investment Research
- Mentions:
EDIT
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
a month ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2 months ago - By: Zacks Investment Research
- Mentions:
URGN
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
2 months ago - By: Zacks Investment Research
- Mentions:
MIRM
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
4 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
5 months ago - By: Zacks Investment Research
- Mentions:
GLUE
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
5 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
5 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
5 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
6 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
6 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
6 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
6 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
7 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
7 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
7 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
7 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
7 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
7 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
9 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
9 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
9 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
9 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
10 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
10 months ago - By: TScan Therapeutics, Inc.
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
Please enable JavaScript to continue using this application.